Research suggests that allantoin may be a potential prognostic biomarker for Parkinson's disease. Additionally, measuring eye movements is being explored as a possible method to track the progression of the disease. The relationship between these two approaches is unclear, but both are being investigated as potential tools for understanding and managing Parkinson's.